Taigen Biopharmaceuticals Holdings Ltd - ESG Rating & Company Profile powered by AI
Detailed ESG assessment of Taigen Biopharmaceuticals Holdings Ltd are accessed by logging in. The webpage includes a Q&A table about Taigen Biopharmaceuticals Holdings Ltd. The ESG rating covers seventeen UN SDGs including: 'Gender Equality', 'Sustainable Cities & Communities' and 'Life below Water'.
Taigen Biopharmaceuticals Holdings Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Taigen Biopharmaceuticals Holdings Ltd | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Taigen Biopharmaceuticals Holdings Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Taigen Biopharmaceuticals Holdings Ltd disclose current and historical energy intensity?
Does Taigen Biopharmaceuticals Holdings Ltd report the average age of the workforce?
Does Taigen Biopharmaceuticals Holdings Ltd reference operational or capital allocation in relation to climate change?
Does Taigen Biopharmaceuticals Holdings Ltd disclose its ethnicity pay gap?
Does Taigen Biopharmaceuticals Holdings Ltd disclose cybersecurity risks?
Does Taigen Biopharmaceuticals Holdings Ltd offer flexible work?
Does Taigen Biopharmaceuticals Holdings Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Taigen Biopharmaceuticals Holdings Ltd disclose the number of employees in R&D functions?
Does Taigen Biopharmaceuticals Holdings Ltd conduct supply chain audits?
Does Taigen Biopharmaceuticals Holdings Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Taigen Biopharmaceuticals Holdings Ltd conduct 360 degree staff reviews?
Does Taigen Biopharmaceuticals Holdings Ltd disclose the individual responsible for D&I?
Does Taigen Biopharmaceuticals Holdings Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Taigen Biopharmaceuticals Holdings Ltd disclose current and / or historical scope 2 emissions?
Does Taigen Biopharmaceuticals Holdings Ltd disclose water use targets?
Does Taigen Biopharmaceuticals Holdings Ltd have careers partnerships with academic institutions?
Did Taigen Biopharmaceuticals Holdings Ltd have a product recall in the last two years?
Does Taigen Biopharmaceuticals Holdings Ltd disclose incidents of discrimination?
Does Taigen Biopharmaceuticals Holdings Ltd allow for Work Councils/Collective Agreements to be formed?
Has Taigen Biopharmaceuticals Holdings Ltd issued a profit warning in the past 24 months?
Does Taigen Biopharmaceuticals Holdings Ltd disclose parental leave metrics?
Does Taigen Biopharmaceuticals Holdings Ltd disclose climate scenario or pathway analysis?
Does Taigen Biopharmaceuticals Holdings Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Taigen Biopharmaceuticals Holdings Ltd disclose the pay ratio of women to men?
Does Taigen Biopharmaceuticals Holdings Ltd support suppliers with sustainability related research and development?
Does Taigen Biopharmaceuticals Holdings Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Taigen Biopharmaceuticals Holdings Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Taigen Biopharmaceuticals Holdings Ltd involved in embryonic stem cell research?
Does Taigen Biopharmaceuticals Holdings Ltd disclose GHG and Air Emissions intensity?
Does Taigen Biopharmaceuticals Holdings Ltd disclose its waste policy?
Does Taigen Biopharmaceuticals Holdings Ltd report according to TCFD requirements?
Does Taigen Biopharmaceuticals Holdings Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Taigen Biopharmaceuticals Holdings Ltd disclose energy use targets?
Does Taigen Biopharmaceuticals Holdings Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Taigen Biopharmaceuticals Holdings Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Taigen Biopharmaceuticals Holdings Ltd
These potential risks are based on the size, segment and geographies of the company.
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. It is also developing Taigexyn for treating community-acquired pneumonia and diabetic foot infection, as well as other bacterial infections; Burixafor, a stem cell mobilizer for stem cell transplantation and chemosenzitization; TG-1000, an influenza antiviral drug for treating influenza A, B, and avian influenza H7N9; and Furaprevir, a hepatitis C virus protease inhibitor for the treatment of chronic hepatitis C. The company was founded in 2001 and is based in Taipei City, Taiwan.